### ü´Å Pulm/CC: Treatment of chronic asthma with inhaled long-acting muscarinic antagonist

#### ‚úÖ True Statements
1. **Inhaled glucocorticoids** are the most effective class of asthma controller medications and should be prescribed in most patients with asthma.
2. A **long-acting muscarinic antagonist (LAMA)** such as tiotropium provides sustained airway dilation, improves lung function, and reduces exacerbations when added to inhaled glucocorticoid‚Äìlong-acting Œ≤2-agonist (LABA) therapy in patients with uncontrolled asthma.
3. A **LAMA should be added** to the treatment regimen when high-dose inhaled glucocorticoid‚ÄìLABA therapy inadequately relieves asthma symptoms.
4. **Triple therapy** with inhaled glucocorticoid, LABA, and LAMA is effective in asthma regardless of blood eosinophil count, and it is not necessary to assess for eosinophilia before adding a LAMA.
5. **Leukotriene receptor antagonists** such as montelukast have modest bronchodilation and are most effective in patients with aspirin-exacerbated respiratory disease; they are not recommended as primary step-up therapy in uncontrolled asthma.
6. **Biologic therapy** is considered when asthma remains difficult to control with maximal medical therapy and is typically directed against type 2 inflammation, targeting eosinophils or IgE pathways.
7. **Omalizumab** is most effective in patients with elevated IgE levels, whereas eosinophil-targeting biologics (e.g., mepolizumab, reslizumab) are most effective in patients with elevated blood eosinophil counts.
8. Evaluation and treatment of **comorbid conditions** such as obstructive sleep apnea are important in all patients with asthma.
9. **Key Point:** The addition of a long-acting muscarinic antagonist in patients with poor asthma control despite high-dose inhaled glucocorticoid‚Äìlong-acting Œ≤2-agonist therapy improves symptom control and lung function and reduces the rate of exacerbation.

#### üí¨ Extra(s)
2. Tiotropium is the specific LAMA with proven benefit as add-on therapy in uncontrolled asthma.
5. Montelukast is useful as add-on therapy but should not be the first choice when high-dose inhaled glucocorticoid‚ÄìLABA therapy fails.
6. Biologic agents should be considered only after maximal inhaled therapy, including the addition of a LAMA.

#### üìö Reference
Kostikas K, Maspero JF, Chapman KR, et al. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: post hoc analysis of IRIDIUM study. Respir Med. 2023;217:107334. PMID: 37392789 doi:10.1016/j.rmed.2023.107334

#### üè∑Ô∏è Tags
#Pulm/CC #Asthma #LAMA #LABA #InhaledGlucocorticoids #BiologicTherapy #AmbulatoryCare

#### üÜî Question ID
PMMCQ24043

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Asthma, Management of Chronic Asthma, Controller Medications for Asthma  

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Controller Medications for Asthma
1. **Inhaled glucocorticoids** are the most effective class of **controller medications** in asthma.  
2. **Active smoking** reduces the effectiveness of inhaled glucocorticoids and may require higher doses.  
3. **Adverse effects of inhaled glucocorticoids** include **oral candidiasis, dysphonia**, and, at higher doses, **systemic effects** such as **adrenocortical suppression, reduced bone mineral density, cataracts, and increased pneumonia risk**.  
4. **LABAs** improve control and reduce exacerbations when combined with inhaled glucocorticoids, but **should not be used alone** because of increased risk of asthma-related death.  
5. **LABAs plus inhaled glucocorticoids in a single inhaler** improve adherence and reduce cost compared with separate inhalers.  
6. **Leukotriene receptor antagonists** have modest bronchodilation effects and are effective in **aspirin-exacerbated respiratory disease**.  
7. **Oral glucocorticoids** should be reserved for acute exacerbations and **avoided long term** due to adverse effects.  
8. **LAMAs (e.g., tiotropium)** improve lung function and reduce exacerbations when added to inhaled glucocorticoid‚ÄìLABA therapy.  
9. **Biologic therapies** (anti-IgE, anti-IL-5, anti-IL-4/IL-13, anti-TSLP) are used in **severe asthma not adequately controlled on standard therapy**.  
10. **Omalizumab** reduces exacerbations and emergency visits in patients with **moderate to severe atopic asthma** not controlled with high-dose inhaled glucocorticoid‚ÄìLABA therapy.  
11. **IL-5 inhibitors (mepolizumab, reslizumab, benralizumab)** and **IL-4/IL-13 inhibitor (dupilumab)** benefit patients with **eosinophilia** (threshold 150‚Äì400/¬µL depending on agent).  
12. **Tezepelumab**, an anti-TSLP biologic, is approved for **severe asthma regardless of phenotype**.  
13. Before biologics, clinicians must verify **adherence**, assess **inhaler technique**, and address **comorbidities**.  

#### üí¨ Extra
3. Systemic effects are uncommon below **400 ¬µg/day budesonide equivalent**.  
4. LABAs are safe when combined with inhaled glucocorticoids (as confirmed in large trials).  
12. Tezepelumab has a broader indication than other biologics because it is not limited to eosinophilic or allergic asthma phenotypes.  

#### üè∑Ô∏è Tags
#Asthma #ControllerMedications #InhaledGlucocorticoids #LABA #LAMA #LeukotrieneAntagonists #Biologics  

---

#### üóæ Supplemental HTML Table(s)

<table>
  <caption><strong>Characteristics of Biologic Agents Indicated to Treat Severe Asthma</strong></caption>
  <thead>
    <tr>
      <th>Biologic Agent</th>
      <th>Target</th>
      <th>Guidelines<sup>b</sup></th>
      <th>Formulation</th>
      <th>Home Use</th>
      <th>Adverse Effects</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Omalizumab</td>
      <td>IgE</td>
      <td>Severe asthma, IgE 30 to 700 U/mL (30-700 kU/L) and atopy</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Anaphylaxis, increased risk of malignancy</td>
    </tr>
    <tr>
      <td>Mepolizumab</td>
      <td>IL-5</td>
      <td>Severe asthma, absolute eosinophils >150/¬µL (0.15 √ó 10<sup>9</sup>/L)</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions, headache, helminth infections</td>
    </tr>
    <tr>
      <td>Reslizumab</td>
      <td>IL-5</td>
      <td>Severe asthma, absolute eosinophils >400/¬µL (0.4 √ó 10<sup>9</sup>/L)</td>
      <td>Intravenous infusion</td>
      <td>No</td>
      <td>Anaphylaxis, headache, helminth infections</td>
    </tr>
    <tr>
      <td>Benralizumab</td>
      <td>IL-5</td>
      <td>Severe asthma, absolute eosinophils >150/¬µL (0.15 √ó 10<sup>9</sup>/L)</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions, helminth infections</td>
    </tr>
    <tr>
      <td>Dupilumab</td>
      <td>IL-4, IL-13</td>
      <td>Moderate to severe asthma, absolute eosinophils >150/¬µL (0.15 √ó 10<sup>9</sup>/L) or dependence on systemic glucocorticoids</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions, helminth infections</td>
    </tr>
    <tr>
      <td>Tezepelumab</td>
      <td>TSLP</td>
      <td>Severe asthma, add-on therapy</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions</td>
    </tr>
  </tbody>
</table>
<p><em>IL = interleukin; TSLP = thymic stromal lymphopoietin.<br>
aSpecialty referral recommended.<br>
bPatients with severe asthma not adequately controlled on standard therapy.</em></p>

#### ‚úÖ True Statements (from Table: Characteristics of Biologic Agents Indicated to Treat Severe Asthma)
1. **Omalizumab** targets **IgE**, is used in **severe asthma with IgE 30‚Äì700 U/mL and atopy**, is given by **subcutaneous injection**, and carries a risk of **anaphylaxis and malignancy**.  
2. **Mepolizumab** targets **IL-5**, is indicated for **severe asthma with eosinophils >150/¬µL**, is given by **subcutaneous injection**, and may cause **hypersensitivity, headache, or helminth infections**.  
3. **Reslizumab** targets **IL-5**, is indicated for **severe asthma with eosinophils >400/¬µL**, is given by **intravenous infusion**, and may cause **anaphylaxis, headache, or helminth infections**.  
4. **Benralizumab** targets **IL-5**, is indicated for **severe asthma with eosinophils >150/¬µL**, is given by **subcutaneous injection**, and may cause **hypersensitivity or helminth infections**.  
5. **Dupilumab** targets **IL-4 and IL-13**, is indicated for **moderate to severe asthma with eosinophils >150/¬µL or glucocorticoid dependence**, is given by **subcutaneous injection**, and may cause **hypersensitivity or helminth infections**.  
6. **Tezepelumab** targets **TSLP**, is indicated as **add-on therapy for severe asthma regardless of phenotype**, is given by **subcutaneous injection**, and may cause **hypersensitivity reactions**.  

#### üè∑Ô∏è Tags
#Asthma #Biologics #Omalizumab #Mepolizumab #Reslizumab #Benralizumab #Dupilumab #Tezepelumab
